Cell-free DNA (cfDNA) testing has become central to modern liquid biopsy workflows, enabling molecular laboratories to detect clinically relevant genomic alterations from plasma samples. As liquid biopsy applications expand across therapy selection, treatment monitoring and molecular residual disease assessment, laboratories must demonstrate that assay performance remains accurate, reproducible and fit for purpose.
Unlike tissue testing, cfDNA assays often operate at the limits of detection. Circulating tumour DNA (ctDNA) may represent less than 1% of total cfDNA, making analytical sensitivity dependent on the entire workflow, from sample collection and extraction through sequencing, bioinformatics and long-term quality monitoring. Robust quality control strategies and well-characterised reference materials are therefore essential for assay validation, verification and ongoing performance monitoring. [1]
:quality(75))
:quality(75))